Nippon Chemiphar Of Japan, Ranbaxy Of India To Part Ways On Nihon
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Nippon Chemiphar and India's Ranbaxy Laboratories are ending their nearly seven-year venture for selling generics in Japan. The two firms share equally in Nihon Pharmaceutical, which they created to market the generics made by Ranbaxy in India. Nippon Chemiphar, in the wake of fellow Japanese drug maker Daiicho Sankyo's purchase of Ranbaxy, now is negotiating with Ranbaxy to buy its 50 percent stake in Nihon. In addition to Ranbaxy's own review of its Japanese operations, the Nihon venture may not have been sufficiently profitable to satisfy Nippon Chemiphar. (Click here for more - a subscription may be required
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.